Mosaic mutations in blood DNA sequence are associated with solid tumor cancers

Area of Science:

• Genetics
• Oncology
• Genomics

Background:

• Somatic protein-truncating DNA variants detected in blood have been causally linked to leukemia.
• The generalizability of these findings across diverse cancer types remains an open question.

Purpose of the Study:

• To investigate the association between mosaic protein-truncating variants in blood DNA and various solid-tumor cancers.
• To determine if these variants are present within tumor tissue and assess their potential role as drivers.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) exome sequencing data from approximately 8000 cancer samples.
• Employed a case-control study design comparing 22 different cancer phenotypes against over 6000 controls.
• Analyzed gene-specificity of mosaic mutations across different cancer types.

Main Results:

• Mosaic protein-truncating variants are significantly associated with solid-tumor cancers, extending previous leukemia findings.
• Absence of these variants within tumor samples suggests they are not tumor drivers.
• Confirmed a specific association between PPM1D variants and ovarian cancer, aligning with prior research.
• Identified gene-specific burdens of mosaic mutations in glioblastoma, melanoma, and lung cancers.

Conclusions:

• Somatic, blood-detectable protein-truncating variants are broadly linked to solid-tumor cancers.
• These findings expand the understanding of blood-based genetic markers in cancer etiology.
• Mosaic mutations in specific genes like PPM1D have distinct associations with particular cancer types.